Fig. 1

Recruitment, inclusion, and randomization of patients in the study. (1) Patients are screened prior to surgery, so glioblastoma (GBM) determination is made from pathological diagnosis after surgery. (2) Insufficient tumor lysate generated to meet threshold. (3) Progressive disease or pseudo-progression (which are indistinguishable at this point) based on central review of MRI imaging at baseline post-chemoradiation. (4) Patients who consented to tumor donation but then declined participation in trial prior to leukapheresis. (5) Includes deviations from standard chemoradiation protocol, history of prior malignancy, inadequate renal or bone marrow function, etc. (6) Includes drug product failure or insufficient drug or placebo manufactured to meet release criteria. (7) Includes clinical deterioration, declining Karnofsky performance status, or patient deaths. (8) Includes biopsy only, surgery canceled, or tumor tissue not processed after surgery